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1.Introduction
The initial clinical description of Down syndrome (DS) was
made by Down in 1866 [1] and identiﬁed as trisomy of
chromosome 21 by Lejeune et al. in 1959 [2]. DS, or tri-
somy 21, is one of the most common causes of intellectual
disability (ID), and recent national prevalence estimates sug-
gest that 14.47 per 10,000 live births are infants with DS,
leading to an average of 6037 annual DS births [3]. This
represents an increase from previous prevalence rates. Cha-
racteristic physical features, deﬁcits in the immune and end-
ocrine systems, and delayed cognitive development [4]c a n
be present in children with DS.
Improvements in medical care for children and adults
with DS have led to signiﬁcant extensions in lifespan and
enhanced quality of life. As a consequence, up to 35 years
of age, mortality rates are comparable in adults with DS to
individuals with ID from other causes. However, after age 35,
mortality rates double every 6.4 years in DS, as compared
to 9.6 years for people without DS [5], and the current-
ly estimated life expectancy of a 1-year-old child with
DS is between 43 and 55 years (depending on the level
of disability). Although longevity in adults with DS has
been increasing progressively, these increases have been sub-
stantially lower for some minority groups [6, 7]. Further, as
described by L. Thorpe et al., adults with DS are still dis-
advantaged compared to adults with other types of ID in
terms of mortality rate, with multiple comorbidities being
of signiﬁcant concern (e.g., depression, seizures). Signiﬁcant
contributors to quality of life in aging individuals with DS
also include gait disturbances (B. A. Smith et al.) and oph-
thalmic disorders (e.g., S. J. Krinsky-MC. Hale et al.), both of
which increase with age.
2. Dementia andAging inDS
A key concern to aging adults with DS is the increasing risk
for developing Alzheimer’s disease (AD). The proﬁle and
sequence of cognitive impairments in adults with DS are
similar to those seen with AD in the general population
[8–13]. Memory processes are aﬀected early in the course
of DS dementia [14]. Severe cognitive deterioration, such as
acquired apraxia and agnosia, has been reported in 28% of
individuals with DS at age 30 years, with a higher prevalence
of these impairments in the subsequent years [8, 9]. The
earliest manifestations of dementia in DS may involve
changes in personality and behavior [15–17]. Pragnosia or
socially deﬁcient communication may be an early sign of
frontal lobe dysfunction in DS and can represent a striking
change from previous well-developed social capacities [18].
Individuals with DS typically show less of a decline in
language compared to performance skills associated with
agingthroughoutadulthoodascomparedtoindividualswith
ID but not DS [19]. The diagnosis of dementia in DS can
be challenging against the background of pre-existing intel-
lectual impairment. Standardized criteria for the diagnosis2 Current Gerontology and Geriatrics Research
of dementia in DS include both informant-based and direct
measures [16, 20–22]. The severity of preexisting cognitive
impairment may also be a predictor of the rate of cognitive
d e t e r i o r a t i o ni nD S[ 23].
Potentially modiﬁable risk factors are now being iden-
tiﬁed that can lead to enhanced susceptibility to dementia
in people with DS [24]. For example, women with DS may
developdementia10–20yearsearlierthanwomeninthegen-
eral population [9, 25, 26]. One possible mechanism under-
lying increasing dementia risk for women with DS is sug-
gested by J. H. Lee et al. The study describes a genetic poly-
morphism in the hydroxysteroid-17β-dehydrogenase gene
that is responsible for converting estrone to estradiol. Poly-
morphisms of this gene may lead to changes in activity of
hydroxysteroid-17β-dehydrogenase and modify circulating
levelsofneuroprotectiveestrogen.Inacohortofwomenwith
DS followed longitudinally, the onset of dementia was linked
to three of ﬁve single nucleotide polymorphisms (SNPs) in
this gene, and women with high-risk SNPs were 2-3 times
more likely to develop AD.
3. Neurobiology of Aging inDS
Middle-aged individuals with DS develop AD pathology
[25, 27–29], no doubt contributing to their high risk of
developing dementia [9, 30]. Still, not every individual
with DS will develop dementia. Although clinical signs of
dementia are more commonly observed when individuals
a r eo v e r5 0y e a r so fa g e[ 9, 31–33], by 40 years of age,
virtually all individuals with DS have neuropathological
changes that are consistent with AD, including senile plaques
andneuroﬁbrillarytangles(NFT)[13,27,28].Senileplaques
contain the beta-amyloid peptide (Aβ) toxic to neurons and
thought to be a causative event in the pathogenesis of AD
[34, 35].
DS involves the overexpression of the amyloid pre-
cursor protein (APP) on chromosome 21. APP is cleaved
sequentially by beta- and gamma-secretases to release Aβ,
which forms toxic conformations and aggregates (e.g.,
senile plaques) in the AD and DS brain [34]. Indeed, the
developmentofADneuropathologyinmostindividualswith
DS after the age of 40 years is considered to be key evidence
in support of the amyloid cascade hypothesis as a cause for
sporadic AD. Beta-secretase has been characterized as the
enzyme beta-amyloid cleaving enzyme (BACE), of which a
homologous version, BACE2, is present on chromosome 21
[36]. However, despite increases in BACE2 mRNA in DS
brain, protein levels appear similar in DS compared to non-
DS brain. Further, BACE2 activity appears to decrease the
production of Aβ from APP in contrast to the activity of
BACE1. R. L. Webb and M. P. Murphy also describe evidence
that BACE activity overall is not increased in the aged DS
brain, leading to the conclusion that APP overexpression
may be the prime cause of Aβ overproduction. It is also
fascinating to consider that despite earlier ages of onset of
Aβ deposition in the brain (∼30 years), people with DS are
able to compensate for progressive AD neuropathology and
many people with DS do not show signs of cognitive decline
until their 50s or even later [24]. Similarly, there are people
without DS who by imaging studies or autopsy examinations
show Aβ deposition in the brain but are clinically normal,
suggesting that similar compensatory processes may also
occur [37–39].
A novel hypothesis is also provided by A. Reed-Cossairt
et al. regarding a role for reduced clearance of Aβ as a con-
sequence of slower cerebrospinal ﬂuid (CSF) turnover. In
addition, vascular dysfunction, speciﬁcally in the jugular
reﬂux, may be a signiﬁcant contributor to slowed CSF turn-
over and the development of dementia in adults with DS. An
additional consequence of reduced vascular function may be
thedevelopmentofwhitematterneuropathologythatistypi-
cally seen in AD. Many gaps in our knowledge regarding
this potential feature of aging in DS that could be modiﬁed
with appropriate interventions are also discussed by Reed-
Cossairt.
Additional neurobiological events that may impact the
risk of dementia may also compromise cognition in DS. As
summarized by J. P. Lockrow et al., a loss of neurons in
the locus coeruleus and basal forebrain (BFCNs) can lead to
reductions in two neurotransmitters that play a critical role
in learning and memory, norepinephrine, and acetylcho-
line. Further, these authors provide additional data suggest-
ing that reduced norepinephrine may also lead to increased
neuroinﬂammation and degeneration in the hippocampus
(another area critical for memory). Reduced neurotransmit-
ter levels in DS may also lead to a loss of trophic support
for neurons in the DS brain with age. Based upon research
i nm o u s em o d e l so fD S( d e s c r i b e di nd e t a i lb yG .N .V a c a n o
et al.), a loss of brain derived neurotrophic factor (BDNF)
occursin response to norepinephrine losses and leads to cog-
nitive deﬁcits. A decrease in BDNF, in turn, has been linked
to enhanced vulnerability of neurons to oxidative stress, sug-
gesting a cycle of increasing insults that may eventually lead
to neurodegeneration or death.
Oxidative damage has been extensively studied in people
with DS, because a signiﬁcant number (>10) of genes
encoding proteins relevant to oxidative damage [40–42]
and ROS production located on chromosome 21 [43].
Many of these are overexpressed in DS. SOD1 has been
perhaps the most studied protein with regard to ROS meta-
bolisminDS.Increasedlevelsofthisendogenousantioxidant
without parallel increases in catalase can lead to higher levels
of hydrogen peroxide. As reviewed by M. Perluigi et al., oxi-
dative damage may be a signiﬁcant contributor to neurode-
generation associated with the AD neuropathology seen
in DS with advancing age. Speciﬁcally, in the aging DS
brain, the presence of age-associated Aβ c a ni nt u r nc a u s e
oxidative damage, but there is also evidence that compensa-
tory mechanisms may support normal neuronal function
until some threshold is crossed. Further, changes in mito-
chondrial functioning may produce damaging free radicals
that contribute to oxidative stress, given that we see higher
levels of mitochondrial DNA mutations in DS (P. E. Coskun
and J. Busciglio), although the combination of mitochon-
drial dysfunction and oxidative stress may lead to adaptive
responses in DS, perhaps prior to the development of
AD.Current Gerontology and Geriatrics Research 3
Aβ and oxidative damage may contribute to brain
inﬂammation, either independently or in concert. Neuroin-
ﬂammation, however, has not been studied as extensively as
these two other markers of neuropathology and represents
an area of focus that may be highly relevant to aging in DS
( D .M .W i l c o c k )[ 44, 45]. Given that genes involved with
neuroinﬂammation are located on chromosome 21, the neu-
roinﬂammatory milieu in DS may be diﬀerent from AD in
the general population. For example, S100β is present in
triplicate in DS, is expressed by astrocytes, and is released
in response to inﬂammatory cytokines. As shown in Table
1 of the review by D. M. Wilcock, this is one of multiple
genes that could lead to enhanced neuroinﬂammation in
DS, although these genes may also prime the brain towards
an M1 inﬂammatory response. Inﬂammatory responses may
lead to enhanced vulnerability of DS neurons in the presence
of Aβ—tangles and oxidative damage—and could be a signi-
ﬁcant target for intervention. Neuroinﬂammation has not
been fully explored as a function of age in DS and is an active
area of research in AD in the general population.
G. Tansley et al. provide novel evidence that circulating
levels of 24S-OH-cholesterol, thought to reﬂect brain levels
of cholesterol, are unchanged in aging individuals with DS
compared to those without DS. Further, the overall lipid
metabolism proﬁle of plasma observed in DS is similar to
thosewithoutDS.Theexceptionmaybebrassicasterollevels,
which are reduced for older DS individuals compared to
those without DS. While this is a very intriguing ﬁnding and
may reﬂect AD-associated neuropathology, this is the ﬁrst
report of the eﬀect and further conﬁrmation is required.
4.PharmacologicalandNonpharmacological
Intervention Strategies
There are only 5 FDA-approved drugs for the treatment
of AD in the general population, and these have met with
moderate or little success for the treatment of AD in DS [46–
51]. This suggests that other disease-modifying approaches
are going to be critically important for future therapeutics.
Prevention,however,maybethemostpromisingapproachto
healthy aging in DS and may include both pharmacological
and nonpharmacological interventions.
Critically important to the development of novel thera-
peutics or prevention strategies is the use of mouse models
for DS where promising strategies can be ﬁrst tested. There
are several mouse models for DS that capture developmental
and aging-associated phenotypes (G. N. Vacano et al.).
Although DS is a complex genetic disorder, carefuldissection
of the role of individual or groups of genes to the DS pheno-
type provides an exciting approach for the development
of new interventions. In combination with existing mouse
modelsforAD,promisingnewpharmacologicalornonphar-
macological treatments may be identiﬁed. However, it is also
critical to note that translation of outcomes from mouse
studies to human clinical trials is not necessarily direct, but
the mouse studies provide important proof of principle out-
comes that can be pursued.
Asoneexampleofusingthisapproach,J .P .Lockro wetal.
review studies suggesting that the norepinephrine precursor
L-threo-DOPS(Droxidopa) canimprovelearningandmem-
ory in DS mice and may be a possible target for DS clinical
trials addressing improvement of age- and AD-associated
cognitive dysfunction. As a parallel component to enhancing
norepinephrine function, neuroinﬂammation appears to be
intimately linked to the levels of this neurotransmitter and
increased in DS aging mice.
Another pharmacological approach to preventing AD
in people with DS may be to modify the production of
Aβ due to overexpression of APP (R. L. Webb and M. P.
Murphy). Clinical trials are currently addressing the reduc-
tion of BACE activity in sporadic cases of AD (http://www
.clinicaltrials.gov/), but gamma-secretase inhibitors may not
be a viable option given adverse side eﬀects. An intriguing
report in a mouse model of DS showed that reducing BACE
activity in young animals reduced learning and memory
deﬁcits, suggesting that APP overexpression and production
of Aβ may not only be involved with AD development with
age but also contribute to intellectual disability in younger
individuals [52].
Reducing oxidative damage (which is a lifelong issue
for DS) may require a multitargeted approach that is pre-
ventative in nature, given that supplementing demented
adults with DS with antioxidants (or individuals with AD in
the absence of DS) has shown little or no beneﬁt to clini-
c a lo u t c o m e s[ 53]. Indeed, compensatory mechanisms at
younger ages in DS may be enhanced by antioxidant supple-
mentation (M. Perluigi and D. A. Butterﬁeld). Focusing on
mitochondrial dysfunction is also a promising approach, as
these organelles arethe primary producers of reactive oxygen
species (P. E. Coskun and J. Busciglio). In addition, isolated
mitochondria have a higher rate of DNA mutations, suggest-
ing a progressive exacerbation in mitochondrial function in
DS. Given this evidence for mitochondrial dysfunction in
DS, there are several possible interventions that may reduce
age-associated declines (e.g., dietary changes and/or supple-
mentation with mitochondrial cofactors). A combinatorial
approach may be particularly valuable for adults with DS
who may beneﬁt from a supplement including both anti-
oxidants (e.g. vitamins E and C) and mitochondrial co-
factors (e.g., lipoic acid, acetylcarnitine). However, it may
be critical to use these approaches as a preventative measure
rather than as a treatment protocol for AD in DS [53]. Given
the interaction between Aβ, oxidative damage and neu-
roinﬂammation, and the relative paucity of data regarding
inﬂammation in the aging DS brain, unexplored potential
new targets for intervention may exist (D. M. Wilcock).
Several key issues highlighted in this special issue topics
suggest that lifestyle modiﬁcation and regular health mon-
itoring may also lead to successful aging in people with
DS. For example, although older adults show decreased
stability and eﬃciency in gait during walking, evidence for
adaptation suggests potential for improvements with appro-
priate interventions (B. A. Smith et al.). Changes in gait
should be taken into consideration, as they may lead to less
physical activity and/or functional decline.
A substantial number of people with DS develop oph-
thalmic disorders, aﬀecting up to 50% of adults between
50 and 59 years of age (S. J. Krinsky-MC. Hale et al.).4 Current Gerontology and Geriatrics Research
The development of age-associated visual deﬁcits occurs at
younger ages in DS than that in the general population.
The presence of ophthalmic disorders is higher in DS indi-
viduals with more severe intellectual disability, leading to
additional challenges and signiﬁcant functional consequen-
ces. Interestingly, in S. J. Krinsky-MC. Hale’s report of longi-
tudinally followed individuals with DS, cataracts were the
most frequent problem in older adults but were not asso-
ciated with the level of ID. However, the presence of cat-
aracts does compromise functioning and readily available
treatmentscanimprovequalityoflifeforaﬀectedindividuals
with DS.
Diet may be a very important area to consider for healthy
aging in DS. For example, the reduced levels of brassicasterol
reported by G. Tansley et al. may be modiﬁable by diet.
Whether this would mechanistically reduce the development
ofADorimpactonlongitudinal changesincognition hasyet
to be determined. Additionally, managing estrogen levels in
agingwomenwithDSmayhelptoreducetheirriskfordevel-
oping AD dementia, but an individualized approach includ-
ing genetic risk as determined by the presence of SNPs on the
HSD17B1genemayneedtobeincorporated(J.H.Leeetal.).
5. Summary
This special issue of the Current Gerontology and Geriatrics
Research journal was intended to cover selected issues deﬁn-
ing the concerns faced by adults with Down syndrome as
they grow older. As can be seen from this selection of papers,
substantial gaps in our knowledge of the aging process in
people with DS continue to persist and are critically impor-
tant to address. Further, approaches for maintaining healthy
aging in individuals with DS may also inform strategies for
enhancing quality of life for other adults with ID or indeed
in the general population. Ongoing longitudinal studies that
monitor changes in health status, cognition, function, the
development of dementia, and mortality will all be critically
important for informing the development of policies and
interventions to promote healthy aging in DS. A key chal-
lenge to aging adults with DS is the increasing risk for devel-
oping dementia; yet our social and medical infrastructure is
not as well prepared for providing care to adults with DS as
they age relative to the outstanding support available to chil-
dren with DS and their families. The use of FDA-approved
treatments for AD in the general population has met with
limited success in people with DS [46]. Therefore, it is criti-
cally important to explore novel interventions and potential
prophylactic approaches that may provide individuals with
DS the best possible opportunity to age gracefully. Such
interventions along with further study of aging, dementia,
and Alzheimer disease in DS are likely to be of fundamental
importance in understanding AD in the general population.
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